Discontinued — last reported Q4 '16

Other

Payments Of Merger Related Costs Financing Activities

Over 4 years (FY 2021 to FY 2025), Payments Of Merger Related Costs Financing Activities shows a downward trend with a -29.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementCash Flow Statement
SectionOther
CategoryCapital Allocation
SignalLower is better
VolatilityVolatile
First reportedQ1 2013
Last reportedQ4 2016

How to read this metric

An increase indicates active M&A activity or significant costs associated with securing acquisition financing.

Detailed definition

Cash outflows specifically categorized as financing activities related to the costs of executing mergers, acquisitions,...

Peer comparison

Varies significantly based on the company's M&A strategy and deal frequency.

Metric ID: other_payments_of_merger_related_costs_financing_activities

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$875.00K$0.00$0.00$0.00$0.00$590.25K$590.25K$590.25K$590.25K$1.29M$0.00$0.00$0.00$855.00K$0.00$0.00$0.00$0.00$0.00$0.00
QoQ Change-100.0%+0.0%+0.0%+0.0%+119.1%-100.0%-100.0%
YoY Change-100.0%+119.1%-100.0%-100.0%-100.0%-33.9%-100.0%
Range$0.00$1.29M
CAGR-100.0%
Avg YoY Growth-59.3%
Median YoY Growth-100.0%

Frequently Asked Questions

What is ResMed's payments of merger related costs financing activities?
ResMed (RMD) reported payments of merger related costs financing activities of $0.00 in Q1 2026.
What is the long-term trend for ResMed's payments of merger related costs financing activities?
Over 4 years (2021 to 2025), ResMed's payments of merger related costs financing activities has grown at a -29.7% compound annual growth rate (CAGR), from $3.50M to $855.00K.
What does payments of merger related costs financing activities mean?
Cash spent on financing-related fees for mergers and acquisitions.